Quick Answer
Protalix BioTherapeutics, Inc. reported Stockholders Equity of $48.23 million for fiscal year 2025.
Protalix BioTherapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $48.23M | +11.6% |
| 2024 | $43.21M | +28.7% |
| 2023 | $33.57M | +415.5% |
| 2022 | -$10.64M | -76.3% |
| 2021 | -$6.04M | +77.7% |
| 2020 | -$27.04M | +61.6% |
| 2019 | -$70.32M | -33.0% |
| 2018 | -$52.88M | -79.5% |
| 2017 | -$29.46M | -195.8% |
| 2016 | -$9.96M | -191.6% |
| 2015 | $10.87M | +119.6% |
| 2014 | -$55.60M | -106.3% |
| 2013 | -$26.95M | -702.7% |
| 2012 | -$3.36M | +87.1% |
| 2011 | -$26.08M | -130.3% |
| 2010 | -$11.32M | -171.3% |
| 2009 | $15.88M | -64.2% |
| 2008 | $44.35M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $52.91M | +63.1% | +6.0% |
| June 30, 2025 | $49.90M | +74.6% | +10.4% |
| March 31, 2025 | $45.21M | +51.8% | +4.6% |
| December 31, 2024 | $43.21M | +28.7% | +33.2% |
| September 30, 2024 | $32.44M | -15.2% | +13.5% |
| June 30, 2024 | $28.58M | -26.7% | -4.0% |
| March 31, 2024 | $29.79M | +2855.0% | -11.3% |
| December 31, 2023 | $33.57M | +415.5% | -12.2% |
- Protalix BioTherapeutics, Inc. showed an increase of +11.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, Protalix BioTherapeutics, Inc.’s stockholders equity has grown by 8.8% (from $44.35 million to $48.23 million).
- The most recent figure is from Protalix BioTherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: